Only a few patients have undergone an intensive gene therapy cure for sickle cell disease since it was approved by the FDA ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.

GT-0002X is under clinical development by Gene Therapy Research Institution and currently in Phase II for Parkinson's Disease.

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration ...

Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two to 17 with type II ...

From a pig kidney transplant to restoring genetic deafness, 2024 was a year full of medical breakthroughs. The breakthroughs ...

Sangamo Therapeutics Inc. fell as much as 67% in extended trading after Pfizer Inc. ended its partnership to develop a new ...

The FDA approved an injectable version of Opdivo, a cancer drug by Bristol Myers Squibb. Axsome plans to seek approval for ...